David Nagel

David’s priority is leading the Protocol and Trial Optimization (POTO) service. In this role he serves clients as oversight director, project manager, and single point of contact. He also engages in continuous innovation for the service, looking for better ways to meet client needs. In 2018, he led a dozen POTOs across four clients. Other roles at PPD have included strategic proposal development as executive commercial strategy lead, focused on partnerships and rare disease opportunities, and as strategic client solutions team leader, focused on driving several strategic PPD corporate initiatives – these included defining strategies for therapeutic differentiation, Evidera integration, and business unit strategies. Prior to joining PPD, David was employed by GlaxoSmithKline for 13 years and held positions within commercial analysis, strategy, and portfolio management across several different therapeutic areas. David holds a bachelor’s degree in mathematics/statistics from Pennsylvania State University, an MEd from Vanderbilt University, and an MBA from Duke University.